# Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis

> **NCT07471503** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 39 (estimated)

## Conditions studied

- Myelofibrosis (MF)
- HSCT

## Interventions

- **DRUG:** Gecacitinib (also known as Jaktinib)

## Key facts

- **NCT ID:** NCT07471503
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-16
- **Primary completion:** 2029-04-01
- **Final completion:** 2030-04-01
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07471503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07471503, "Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT07471503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*